17-HPC Formulation Modulating Cytokine Storm Mediators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for safely and effectively mitigating proinflammatory responses associated with cytokine storms, which can be triggered by infections or certain drugs, leading to severe conditions such as cytokine release syndrome and multiple organ failure.
Innovation Solution
Compositions comprising 17-alpha hydroxyprogesterone caproate (17-HPC) combined with solubilizing agents and lipophilic agents, administered via soft gelatin capsules or as part of a 2-component solvent system, are used to modulate cytokine mediators and treat cytokine storms and related respiratory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to mitigate proinflammatory responses, then treatment is provided, but safety and effectiveness are inadequate
Solution Approach 1:
The patent changes the chemical parameter of the progestogen by using 17-alpha hydroxyprogesterone caproate with specific esterification at the 17-alpha position, and modifies the formulation parameters by combining it with solubilizing agents and lipophilic agents to achieve effective mitigation of proinflammatory responses
Solution Approach 2:
The patent creates a composite pharmaceutical formulation by combining 17-HPC with solubilizing agents (such as polysorbate 80) and lipophilic agents (such as macrogolglycerol ricinolate), achieving synergistic effects that improve both safety and effectiveness in mitigating cytokine storms
2Reliability
If 17-HPC compositions are administered, then cytokine mediator levels are reduced, but formulation complexity increases due to need for solubilizing and lipophilic agents
Solution Approach 1:
The patent merges multiple functional components into a single integrated formulation: 17-HPC provides the therapeutic effect, solubilizing agents ensure proper dissolution and bioavailability, and lipophilic agents enhance tissue penetration and sustained release, all working together in one composition
Solution Approach 2:
The solubilizing agents and lipophilic agents act as intermediaries that facilitate the delivery and absorption of 17-HPC, enabling the active ingredient to reach its target effectively while maintaining formulation stability
Data Source
AI summary
Disclosed herein, in certain embodiments, are compositions, solutions, and soft gelatin capsules comprising 17-alpha hydroxyprogesterone caproate (17-HPC). In certain embodiments, also disclosed herein are methods, dosing regimens, and kits for use in the treatment of a disease or condition.